Document is current

Article History

Received: 20 September 2024

Accepted: 11 June 2025

First Online: 18 June 2025

Declarations

:

: This SWAT was granted favourable ethical opinion by the National Research Ethics Committee & Health Research Authority (London—Surrey Research Ethics Committee/19/LO/0750) as part of the ethical approval for the host RCT, including permission not to inform participants that they were randomised in the SWAT.

: Not applicable.

: Laura Miller: None.Ailsa Hart: has served as consultant, advisory board member or speaker for AbbVie, Arena, Atlantic, Bristol-Myers Squibb, Celgene, Celltrion, Falk, Galapogos, Lilly, Janssen, MSD, Napp Pharmaceuticals, Pfizer, Pharmacosmos, Shire and Takeda. She also serves on the Global Steering Committee for Genentech.Fionn Cléirigh-Büttner: None.Catherine Arundel: None.Thomas Hamborg: None.Serena McGuinness: None.Rona Moss-Morris: beneficiary of licence between King’s College London and Mahana Therapeutics, consulting fees—Mahana Therapeutics, 11 London. Payment or honoraria for lectures, presentations, or educational events—EAPM and BABCP conferences, Central and North West London NHS Foundation Trust.Adwoa Parker: holds a NIHR Advanced Fellowship (NIHR302256), and received funding from the MRC and NIHR as part of being a co-applicant on this PROMETHEUS programme (MR/R013748/1).Clare Relton: None.Imogen Stagg: None.Louise Sweeney: None.Vari Wileman: None.Zohra Zenasni: None.Christine Norton: speakers fees from: Janssen; WebMD; Medscape; Merck Pharmaceuticals; Tillotts Pharma UK, Lilly Pharmaceuticals. Pfizer: advisory board.